

# BCBSMT HEDIS® 2013 COMPARISON REPORT - Managed Care

## EFFECTIVENESS OF CARE MEASURES

	BCBSMT 2011		BCBSMT 2012		% change	BCBSMT 2013		% change	2012 QC National	2013 QC National			
	Num	Denom	Num	Denom		Num	Denom						
<b>Childhood Immunization</b>	<b>n=71</b>		<b>n=51</b>			<b>n=31</b>							
DTaP	59	71	83.10%	43	51	84.31%	1.46%	26	31	83.87%	-0.52%	86.50%	87.20%
Hib	66	71	92.96%	46	51	90.20%	-2.97%	30	31	96.77%	7.29%	94.10%	94.30%
IPV	68	71	95.77%	45	51	88.24%	-7.86%	30	31	96.77%	9.67%	92.40%	92.80%
PCV	61	71	85.92%	43	51	84.31%	-1.87%	27	31	87.10%	3.31%	87.00%	86.70%
HepB	67	71	94.37%	45	51	88.24%	-6.50%	30	31	96.77%	9.67%	87.90%	89.20%
MMR	66	71	92.96%	48	51	94.12%	1.25%	29	31	93.55%	-0.61%	91.50%	91.80%
VZV	62	71	87.32%	44	51	86.27%	-1.20%	29	31	93.55%	8.44%	91.30%	91.60%
HepA^	27	71	38.03%	21	51	41.18%	8.28%	28	31	90.32%	119.34%	39.00%	65.50%
Rotavirus	44	71	61.97%	39	51	76.47%	23.40%	21	31	67.74%	-11.41%	75.10%	76.70%
Influenza	39	71	54.93%	25	51	49.02%	-10.76%	20	31	64.52%	31.61%	61.10%	63.30%
Combo-1	57	71	80.28%	41	51	80.39%	0.14%	25	31	80.65%	0.32%	na	na
Combo-2	56	71	78.87%	39	51	76.47%	-3.04%	25	31	80.65%	5.46%	78.00%	79.70%
Combo-3	53	71	74.65%	38	51	74.51%	-0.19%	25	31	80.65%	8.23%	75.70%	76.80%
Combo-4 ^	23	71	32.39%	16	51	31.37%	-3.15%	23	31	74.19%	136.51%	na	na
Combo-5	38	71	53.52%	34	51	66.67%	24.57%	18	31	58.06%	-12.91%	na	na
Combo-6	35	71	49.30%	22	51	43.14%	-12.49%	17	31	54.84%	27.12%	na	na
Combo-7 ^	20	71	28.17%	15	51	29.41%	4.40%	17	31	54.84%	86.46%	na	na
Combo-8 ^	15	71	21.13%	10	51	19.61%	-7.19%	16	31	51.61%	163.20%	na	na
Combo-9	25	71	35.21%	21	51	41.18%	16.96%	12	31	38.71%	-6.00%	na	na
Combo-10 ^	12	71	16.90%	10	51	19.61%	16.04%	11	31	35.48%	80.95%	22.90%	37.90%
<b>Adolescent Immunizations</b>	<b>n=110</b>		<b>n=65</b>			<b>n=55</b>							
Meningococcal (MCV)	53	110	48.18%	39	65	60.00%	24.53%	30	55	55.45%	-7.58%	61.90%	66.00%
Tdap/Td	93	110	84.55%	54	65	83.08%	-1.74%	44	55	80.00%	-3.71%	77.00%	79.20%
Combo-1	53	110	48.18%	38	65	58.46%	21.34%	29	55	52.73%	-9.80%	59.40%	63.70%
<b>HPV Vaccine for Female Adolescents</b>	<b>na</b>		<b>n=28</b>			<b>n=31</b>							
	na	na	na	8	28	28.57%	na	6	31	19.35%	-32.25%	na	na
<b>Appropriate Tx for Children w/ URI</b>	<b>n=126</b>		<b>n=114</b>			<b>n=53</b>							
	111	126	88.10%	93	114	81.58%	-7.40%	44	53	83.02%	1.76%	83.90%	84.00%
<b>Appropriate Testing for Children w/ Pharyngitis</b>	<b>n=107</b>		<b>n=116</b>			<b>n=52</b>							
	81	107	75.70%	89	116	76.72%	1.35%	32	52	61.54%	-19.79%	80.20%	80.20%
<b>Avoidance of Antibiotic Tx for Adults w/ Acute Bronchitis</b>	<b>n=122</b>		<b>n=70</b>			<b>n=66</b>							
	24	122	19.67%	7	70	10.00%	-49.16%	11	66	16.67%	66.70%	23.50%	24.60%
<b>Colorectal Cancer Screening</b>	<b>n=2105</b>		<b>n=601</b>			<b>n=1153</b>							
	1190	2105	56.53%	303	601	50.42%	-10.81%	657	1153	56.98%	13.01%	62.40%	63.30%



**EFFECTIVENESS OF  
CARE MEASURES**
**BCBSMT  
2011**
**BCBSMT  
2012**
**BCBSMT  
2013**
**2012 QC  
National**
**2013 QC  
National**

	Num	Denom		Num	Denom		% change	Num	Denom		% change		
Ages 51-64	na	na	na	8	9	88.89%	na	15	19	78.95%	-11.19%	93.20%	92.40%
Combined ***	74	78	94.87%	23	26	88.46%	-6.76%	31	49	63.27%	-28.48%	91.90%	91.20%
<b>Use of Spirometry in the Assessment &amp; Diagnoses of COPD</b>			<b>n=27</b>	<b>n=25</b>				<b>n=29</b>					
	7	27	25.93%	10	25	40.00%	54.26%	17	29	58.62%	46.55%	42.90%	43.50%
<b>Pharmacotherapy Management of COPD Exacerbation</b>			<b>n=4</b>	<b>n=6</b>				<b>n=2</b>					
Bronchodilator	4	4	100.00%	5	6	83.33%	-16.67%	2	2	100.00%	20.00%	79.90%	80.80%
Systemic Corticosteroid	4	4	100.00%	5	6	83.33%	-16.67%	2	2	100.00%	20.00%	71.30%	73.50%
<b>Chlamydia Screening</b>			<b>n=315</b>	<b>n=98</b>				<b>n=135</b>					
Ages 16-20	57	141	40.43%	14	41	34.15%	-15.53%	17	57	29.82%	-12.67%	41.50%	41.10%
Ages 21-24	65	174	37.36%	22	57	38.60%	3.32%	33	78	42.31%	9.61%	48.40%	49.20%
Combined	122	315	38.73%	36	98	36.73%	-5.16%	50	135	37.04%	0.84%	45.00%	45.10%
<b>Use of Imaging Studies for Low Back Pain</b>			<b>n=74</b>	<b>n=78</b>				<b>n=78</b>					
	62	74	86.78%	59	78	75.64%	-12.84%	58	69	84.06%	11.13%	74.40%	75.30%
<b>DMARD Therapy in Rheumatoid Arthritis</b>			<b>n=31</b>	<b>n=9</b>				<b>n=17</b>					
	30	31	96.77%	8	9	88.89%	-8.14%	15	17	88.24%	-0.74%	87.60%	87.90%
<b>Annual Monitoring for Patients on Persistent Medications</b>			<b>n=1066</b>	<b>n=321</b>				<b>n=591</b>					
ACE/ARB	461	581	79.35%	146	176	82.95%	4.54%	286	336	85.12%	2.61%	82.50%	82.90%
Anticonvulsant	15	25	60.00%	5	8	62.50%	4.17%	6	8	75.00%	20.00%	60.50%	58.80%
Digoxin	15	16	93.75%	4	4	100.00%	6.67%	13	14	92.86%	-7.14%	85.40%	86.50%
Diuretic	355	444	79.95%	108	133	81.20%	1.56%	198	233	84.98%	4.65%	82.10%	82.50%
Combined	846	1066	79.36%	263	321	81.93%	3.24%	503	591	85.11%	3.88%	81.90%	82.30%

\* Note: For this numerator, a lower rate indicates better performance.

\*\* Note: The HbA1c < 7.0% denominator excludes members w/ certain conditions. Please see measure description for a list of conditions.

\*\*\* Note: The combined age range for this measure changed from 5-50 years in 2011 to 5-64 years in 2012 & 2013.

^The NCQA qualifying dosing requirements for the Hepatitis A immunizations series changed from 2 doses in 2011 & 2012 to 1 dose in 2013.

BCBSMT 2011 rates based on 2010 data.

BCBSMT 2012 rates based on 2011 data.

BCBSMT 2013 rates based on 2012 data.

The 2013QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2013 Report* and reflect 2012 data.

The 2012 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2012 Report* and reflect 2011 data.